Global Polycystic Ovary Syndrome (PCOS) Treatment Market Size is valued at USD 4.5 Billion in 2024 and is predicted to reach USD 8.0 Billion by the year 2034 at a 6.1% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
Women of childbearing age frequently have polycystic ovarian syndrome (PCOS), a hormonal disorder. Menstrual cycles that are irregular or prolonged, as well as excessive levels of male hormones, might be caused by PCOS. There is no known treatment for PCOS, but several medications control its symptoms and menstrual cycle. An increase in PCOS prevalence, an increase in patient population knowledge, and an increase in the use of combination therapy are the major factors driving the growth of the polycystic ovarian syndrome treatment market. Advances in PCOS screening technology, the rise in demand for PCOS medications, and the accessibility of PCOS treatment also impact the market's expansion. However, it is anticipated that market growth will be constrained by the lack of approved treatments and PCOS's uncertain pathophysiology and etiology.
Additionally, during the projected period, the unrealized potential of developing economies presents lucrative market growth opportunities. As the prevalence of polycystic ovarian syndrome (PCOS) rises, so is the need for treatment. However, the absence of specialized treatment for PCOS disease is anticipated to impede market expansion.
The polycystic ovary syndrome (PCOS) treatment market is segmented on the drug class and distribution channel. Based on drug class, the market is segmented into oral contraceptives, insulin sensitizing agents, antidepressants, ornithine decarboxylase inhibitors, aromatase inhibitors & SERMs and diuretics. Based on distribution channel, polycystic ovary syndrome (PCOS) treatment market is segmented into hospital pharmacies, drug stores/OTC, e-commerce and clinics.
Based on drug class, the market is segmented into oral contraceptives, insulin-sensitizing agents, antidepressants, ornithine decarboxylase inhibitors, aromatase inhibitors & SERMs and diuretics. The insulin-sensitizing agent's category grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the anticipated time. Numerous items are offered for sale, including Glucophage X.R. (Metformin) and other items that contain Troglitazone, Rosiglitazone, and Pioglitazone. Metabolic dysfunction in PCOS may cause an overproduction of androgen, impacting insulin secretion and raising the risk of diabetes. As a result, insulin-sensitizing drugs are crucial for therapeutics because they balance hormone levels, lower insulin levels, and reduce ovarian androgen production.
Based on the distribution channel, the polycystic ovary syndrome (PCOS) treatment market is segmented into hospital pharmacies, drug stores/OTC, e-commerce and clinics. The e-commerce category is anticipated to grow significantly over the forecast period because more people prefer buying medicines online over traditional means, more people are aware of online sources, and more people are using the internet.
The Asia Pacific polycystic ovary syndrome (PCOS) treatment market is expected to register the highest market share in revenue shortly. The market will expand due to the rising acceptance of products for treating polycystic ovarian syndrome and increased knowledge of the treatment. The development of the R&D sector, the expansion of the target population, the growth of healthcare reforms, and technological developments in the healthcare industry all contribute to the market's expansion. Additionally, North America is anticipated to expand at a significant rate over the course of the forecast period. Factors like the increased focus of major manufacturers on growing their geographic presence in developing Asia-Pacific nations to seize a large population base, high growth opportunities in the market, and high disposable incomes are also anticipated to propel the growth of the market in the region.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 4.5 Billion |
|
Revenue Forecast In 2034 |
USD 8.0 Billion |
|
Growth Rate CAGR |
CAGR of 6.1% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn, and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Drug Class, Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Novartis AG, Sanofi, Teva Pharmaceutical Industries Limited, Merck & Co., Inc. (Merck group), AstraZeneca plc., Bayer AG. Abbott, Pfizer, Inc, Bristol-Myer Squibb Company, Ferring Pharmaceuticals, Inc., Johnson and Johnson, Mylan N.V., Allergan plc., GlaxoSmithKline, Lupin Pharmaceuticals, AbbVie, Takeda, BIOCAD Global, Blairex Laboratories Inc and Agile Therapeutics |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Snapshot
Chapter 4. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Drug Class Estimates & Trend Analysis
5.1. by Drug Class & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Drug Class:
5.2.1. Oral Contraceptives
5.2.2. Insulin Sensitizing Agents
5.2.3. Antidepressants
5.2.4. Ornithine Decarboxylase Inhibitors
5.2.5. Aromatase Inhibitors & SERMs
5.2.6. Diuretics
Chapter 6. Market Segmentation 2: by Distribution channel Estimates & Trend Analysis
6.1. by Distribution channel & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Distribution channel:
6.2.1. Hospital Pharmacies
6.2.2. Drug Stores/OTC
6.2.3. e-Commerce
6.2.4. Clinics
Chapter 7. Polycystic Ovary Syndrome (PCOS) Treatment Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2021-2034
7.1.2. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution channel, 2021-2034
7.1.3. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Drug Class, 2021-2034
7.2.2. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Distribution channel, 2021-2034
7.2.3. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Drug Class, 2021-2034
7.3.2. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Distribution channel, 2021-2034
7.3.3. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Drug Class, 2021-2034
7.4.2. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Distribution channel, 2021-2034
7.4.3. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Drug Class, 2021-2034
7.5.2. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Distribution channel, 2021-2034
7.5.3. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1.
8.2.2. Novartis AG
8.2.3. Sanofi
8.2.4. Teva Pharmaceutical Industries Limited
8.2.5. Merck & Co., Inc. (Merck group)
8.2.6. AstraZeneca plc.
8.2.7. Bayer AG
8.2.8. Abbott
8.2.9. Pfizer, Inc
8.2.10. Bristol-Myer Squibb Company
8.2.11. Ferring Pharmaceuticals, Inc.
8.2.12. Johnson and Johnson
8.2.13. Mylan N.V.
8.2.14. Allergan plc.
8.2.15. GlaxoSmithKline
8.2.16. Lupin Pharmaceuticals
8.2.17. AbbVie
8.2.18. Takeda
8.2.19. BIOCAD Global
8.2.20. Blairex Laboratories Inc
8.2.21. Agile Therapeutics
8.2.22. Other Prominent Players
By Drug Class-
By Distribution channel-
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
